Skip to main content

Table 2 Crude odds ratios (OR) for a successful outcome at one year predicted by characteristics at baseline, 4 months, and 1 year

From: Non-face-to-face treatment of stress urinary incontinence: predictors of success after 1 year

  PGI-I ICIQ-UI SF Sufficient treatment
Predictor Success (n = 55) Failure (n = 113) OR (95 % CI) Success (n = 95) Failure (n = 71) OR (95 % CI) Success (n = 93) Failure (n = 69) OR (95 % CI)
Baseline characteristics
  Age (years) 53.45 ± 9.50* 48.73 ± 10.67* 1.05 (1.02–1.09)* 50.98 ± 10.12** 49.63 ± 10.09** 1.01(0.98–1.05)** 53.68 ± 10.06* 46.04 ± 8.61* 1.09(1.05–1.13)*
  Motivation
    1–8 12 (26.1)** 34 (73.9)** 1.00** 15 (34.1)* 29 (65.9)* 1.00*** 19 (45.2)** 23 (54.8)** 1.00**
    9 9 (28.1)** 23 (71.9)** 1.11 (0.40–3.05)** 21 (65.6)* 11 (34.4)* 3.69 (1.41–9.64)* 18 (58.1)** 13 (41.9)** 1.68 (0.66–4.28)**
    10 34 (38.2)*** 55 (61.8)*** 1.75 (0.80–3.84)*** 59 (66.3)* 30 (33.7)* 3.80 (1.77–8.15)* 55 (62.5)** 33 (37.5)** 2.02 (0.96–4.25)**
  Self-rated ability to do PFMT
    1–9 25 (28.7)*** 62 (71.3)*** 1.00*** 39 (45.9)* 46 (54.1)* 1.00* 40 (48.8)* 42 (51.2)* 1.00***
    10 30 (37.5)*** 50 (62.5)*** 1.49 (0.78–2.85)*** 56 (70.0)* 24 (30.0)* 2.75 (1.45–5.22)* 52 (65.8)* 27 (34.2)* 2.02 (1.07–3.82)*
  Vaginal delivery >4,000 g
    No 36 (34.6)** 68 (65.4)** 1.00** 64 (61.5)*** 40 (38.5)*** 1.00*** 53 (52.5)*** 48 (47.5)*** 1.00***
    Yes 13 (26.5)** 36 (73.5)** 0.68 (0.32–1.45)** 22 (46.8)*** 25 (53.2)*** 0.55 (0.27–1.10)*** 29 (63.0)*** 17 (37.0)*** 1.55 (0.76–3.16)***
  Menopause
    No 26 (27.7)*** 68 (72.3)*** 1.00*** 49 (53.8)** 42 (46.2)** 1.00** 39 (43.8)* 50 (56.2)* 1.00*
    Yes 27 (39.1)*** 42 (60.9)*** 1.68 (0.87–3.26)*** 42 (60.0)** 28 (40.0)** 1.29 (0.68–2.42)** 51 (75.0)* 17 (25.0)* 3.85 (1.93–7.67)*
  Local estrogen
    No 43 (29.9)* 101 (70.1)* 1.00* 79 (56.0)** 62 (44.0)** 1.00** 74 (53.6)* 64 (46.4)* 1.00*
    Yes 11 (52.4)* 10 (47.6)* 2.58 (1.02–6.53)* 15 (68.2)** 7 (31.8)** 1.68 (0.65–4.38)** 17 (81.0)* 4 (19.9)* 3.68 (1.18–11.49)*
  Moderate physical activity
    < 3 h/week 23 (40.4)*** 34 (59.6)*** 1.00*** 36 (63.2)* 21 (36.8)* 1.00* 33 (57.9)** 24 (42.1)** 1.00**
    3–5 h/week 15 (27.8)*** 39 (72.2)*** 0.57 (0.26–1.26)*** 23 (42.6)* 31 (57.4)* 0.43 (0.20–0.93)* 26 (51.0)** 25 (49.0)** 0.76 (0.35–1.62)**
      >5 h/week 17 (29.8)*** 40 (70.2)*** 0.63 (0.29–1.37)*** 36 (65.5)** 19 (34.5)** 1.11 (0.51–2.40)** 34 (63.0)** 20 (37.0)** 1.24 (0.58–2.65)**
  Tea, cups/day
    None 18 (34.0)** 35 (66.0)** 1.00** 33 (63.5)** 19 (36.5)** 1.00** 29 (56.9)*** 22 (43.1)*** 1.00***
    1–2 24 (28.9)** 59 (71.1)** 0.79 (0.38–1.66)** 44 (53.0)*** 39 (47.0)*** 0.65 (0.32–1.32)*** 43 (51.8)** 40 (48.2)** 0.82 (0.40–1.65)**
    ≥ 3 13 (40.6)** 19 (59.4)** 1.33 (0.54–3.29)** 18 (58.1)** 13 (41.9)** 0.80 (0.32–1.98)** 21 (75.0)*** 7 (25.0)*** 2.28 (0.82–6.31)***
  ICIQ-UI SF 10.18 ± 3.37** 10.11 ± 3.13** 1.01 (0.91–1.11)** 11.51 ± 2.62* 8.35 ± 2.62* 1.49 (1.30–1.71)* 9.80 ± 3.45*** 10.54 ± 2.88*** 0.93 (0.84–1.03)***
  ICIQ-LUTSqol 33.44 ± 8.40** 32.30 ± 5.85** 1.03 (0.98–1.07)** 34.49 ± 7.18* 30.48 ± 5.55* 1.11 (1.05–1.18)* 32.73 ± 7.63** 32.83 ± 5.79** 0.10 (0.95–1.04)**
4-month follow-up
  PGI-I
    Little better/much worse 21 (19.6)* 86 (80.4)* 1.00* 53 (49.5)* 54 (50.5)* 1.00* 46 (44.2)* 58 (55.8)* 1.00*
    Much better/very much better 33 (55.0)* 27 (45.0)* 5.00 (2.49–10.05)* 41 (70.7)* 17 (29.3)* 2.46 (1.24–4.85)* 46 (80.0)* 11 (19.3)* 5.27 (2.46–11.31)*
  MID ICIQ-UI SF
    <3 18 (26.5)*** 50 (73.5)*** 1.00*** 21 (31.3)* 46 (68.7)* 1.00* 32 (48.5)*** 34 (51.5)*** 1.00***
    ≥3 37 (37.4)*** 62 (62.6)*** 1.66 (0.84–3.26)*** 73 (74.5)* 25 (25.5)* 6.40 (3.22–12.72)* 60 (63.2)*** 35 (36.8)*** 1.82 (0.96–3.45)***
  MID ICIQ-LUTSqol
    < 4 17 (23.3)* 56 (76.7)* 1.00* 30 (41.1)* 43 (58.9)* 1.00* 31 (43.7)* 40 (56.3)* 1.00*
    ≥ 4 37 (39.4)* 57 (60.6)* 2.14 (1.08–4.23)* 65 (69.9)* 28 (30.1)* 3.33 (1.75–6.33)* 62 (68.1)* 29 (31.9)* 2.76 (1.45–5.25)*
  Sufficient treatment
    No 13 (21.7)* 47 (78.3)* 1.00* 30 (50.8)*** 29 (49.2)*** 1.00*** 16 (27.1)* 43 (72.9)* 1.00*
    Yes 42 (40.0)* 63 (60.0)* 2.41 (1.16–4.99)* 63 (60.6)*** 41 (39.4)*** 1.49 (0.78–2.82)*** 77 (76.2)* 24 (23.8)* 8.62 (4.14–17.97)*
1-year follow-up
  PFMT last 3 months
    Less than one time/week 30 (26.5)* 83 (73.5)* 1.00* 62 (54.9)** 51 (45.1)** 1.00** 53 (49.1)* 55 (50.9)* 1.00*
    Regularly, at least one time/week 24 (45.3)* 29 (54.7)* 2.29 (1.16–4.53)* 33 (63.5)** 19 (36.5)** 1.43 (0.73–2.81)** 40 (75.5)* 13 (24.5)* 3.19 (1.54–6.63)*
  1. Values are presented as means (± standard deviation) or n (%)
  2. ORs are the result of univariate logistic regression and are presented with a 95 % confidence interval (CI)
  3. PGI-I Patient Global Impression of Improvement, PFMT pelvic floor muscle training
  4. *p <0.05
  5. **p >0.25
  6. ***p <0.25